Cardiac transplant rejection

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update Financial and business highlights Total H1 2024 incomes of €82.5 million thanks to Company’s new partnerships.New strategic partnership with AbbVie for up to $713 million, including $48 million received upon signature.Major partnership expansion with Boehringer Ingelheim: Amendment of the collaboration and licensing agreement on first-in-class SIRPα compounds developed both in immuno-oncology and now expected in Phase 2 in cardiovascular-renal-metabolic diseases: a one-time payment of €25.3 million.New asset acquisition of a preclinical program from the OSE’s cis- targeting anti-PD1/cytokine platform: €13.5 million received upon signature and €17.5 potential near-term milestone. €8.4 million in non-dilutive funding under the “i-Démo” call for projects as part of the “France 2030” program to support the registration Phase 3 clinical trial of cancer vaccine Tedopi®. Level of cash of €80.7 million as of June 30, 2024: €25.9 million available cash1 + €54.9 million financial assets2, providing solid financial position and visibility to support implementation of the strategy until 2027. This cash position also includes the research tax credit of €5.8 million received in June 2024. Clinical pipeline highlights Positive efficacy and safety results from the Phase 1/2 clinical trial evaluating PD1- antagonist antibody OSE-279 monotherapy in solid tumors.Positive results from the FIRsT Phase 1/2 study from first use of FR104/VEL-101 immunotherapy in renal transplantation. Main post-semester highlights First positive efficacy results from the CoTikiS Phase 2 study evaluating IL-7R antagonist Lusvertikimab in ulcerative colitis. Global launch of Artemia Phase 3 registration study for cancer vaccine Tedopi® in second-line non-small cell lung cancer. NANTES, France, September 26, 2024 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported its consolidated half-year financial results and provided updates on key milestones achieved during the H1 2024 as well as the Company’s outlook for its immunotherapies in immuno-oncology and immuno-inflammation. Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: “The major milestones achieved during H1 2024 are paving the way for a transformative year for OSE. During this period, thanks to the OSE teams, the Company made significant outstanding progress. The half-year has seen continued execution of our partnership-focused business model through three strategic pharmaceutical agreements with major partners, AbbVie and Boehringer Ingelheim, related to our differentiated immunological pipeline. These key achievements trigger a solid financial position supporting the Company’s growth, relying on our promising clinical and preclinical proprietary programs in immuno-inflammation and immuno-oncology conducted and supported by highly skilled OSE teams. We also achieved two significant inflection points on our late-stage proprietary clinical assets. In immuno-inflammation, the positive clinical efficacy and safety results for Lusvertikimab in ulcerative colitis represent a strong catalyst for potential future partnership opportunities. We have generated exciting data that we plan to communicate with our investigators at an upcoming global medical conference. In immuno-oncology, the international registration study Artemia for cancer vaccine Tedopi® in second-line non-small cell lung cancer treatment is now on track globally. In parallel, in order to ensure continuous portfolio development, we continue accelerating and strengthening first-in-class preclinical programs from our innovative research platforms”. Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, said: “With more than €90 million non-dilutive cash-in in 2024, our financial visibility is strongly reinforced until 2027. This allows us to prioritize funding of our recently globally launched Artemia Phase 3 registration study for our cancer vaccine Tedopi® in lung cancer and to further invest in our other proprietary clinical products and innovative R&D engine to increase the value and interest of our assets.” THREE PHARMACEUTICAL AGREEMENTS SIGNED DURING H1 2024 PROVIDING A SOLID FINANCIAL POSITION TO SUPPORT IMPLEMENTATION OF THE STRATEGY UNTIL 2027 In February 2024, OSE Immunotherapeutics and AbbVie concluded a strategic partnership to develop OSE-230 (renamed ABBV-230), a monoclonal antibody designed to resolve chronic and severe inflammation. Under the terms of the agreement, AbbVie received an exclusive global license to develop, manufacture and commercialize ABBV-230. OSE Immunotherapeutics received a $48 million upfront payment and will be eligible to receive up to an additional $665 million in clinical development, regulatory and commercial milestones. In addition, OSE Immunotherapeutics will be eligible to receive potential tiered royalties on global net sales of ABBV-230. In May 2024, OSE Immunotherapeutics and Boehringer Ingelheim expanded their partnership through the addition of two new projects: A new preclinical program will be launched to develop immune-cell activating treatments based on OSE’s cis-targeting3 anti-PD1/cytokine platform via an asset acquisition. Under the terms of this preclinical asset acquisition, OSE Immunotherapeutics received €13.5 million in upfront payment and a potential near-term milestone of EUR 17.5 million. An amendment to the existing collaboration and license agreement for the anti-SIRPα immuno-oncology compounds BI 765063 and BI 770371 (being investigated in Phase 1b clinical studies in advanced solid tumors), development will now also be pursued in cardiovascular-renal-metabolic (CRM) diseases with the initiation of a Phase 2 clinical study planned for end of 2024. Under the terms of this amendment, the parties agreed on partial royalty buy-out monetizing with a one-time payment of EUR 25.3 million. Furthermore, Boehringer is granted an option for an additional buy-out during further development triggering a one-time payment plus the increase of one sales milestone. All other agreed development, regulatory and sales milestone payments of up to €1.1 billion remain as agreed between the parties under the initial agreement. UPDATE ON CLINICAL PROGRESS IN IMMUNO-ONCOLOGY AND IMMUNO-INFLAMMATION First positive efficacy results from the Phase 2 clinical trial evaluating Lusvertikimab in ulcerative colitis. Following completion of enrolment in March 2024, OSE Immunotherapeutics announced in July first positive efficacy results for Lusvertikimab in the Phase 2 trial for the treatment of ulcerative colitis (CoTikiS study): Lusvertikimab demonstrated significant efficacy during the 10 week-induction phase of treatment measured by the improvement of the Modified Mayo Score, in the randomized double blind study,A favorable safety and tolerability profile was observed in the whole patient population across the two doses tested and during the open label phase of treatment. Global launch of the Artemia Phase 3 registration trial for the off-the-shelf neo-epitope-based cancer vaccine Tedopi® in second-line non-small cell lung cancer (NSCLC) after secondary resistance to immune checkpoint inhibitors (ICI). In September 2024, the Company launched its international Phase 3 clinical trial named ‘Artemia’ of Tedopi® in second-line treatment in HLA-A2 positive patients with metastatic NSCLC. This dossier, reviewed and accepted in 14 countries by international health agencies (US FDA, Canada, Europe and the United Kingdom) is a pivotal study supporting the registration of Tedopi®, in parallel with the companion diagnostic for HLA-A2 positive patients.Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors. OSE-279, proprietary anti-PD1: positive efficacy and safety results from Phase 1/2 study in advanced solid tumors. In February 2024, updated positive results from Phase 1/2 of OSE-279 were presented at the ESMO Targeted Anticancer Therapy Congress. These results showed a good pharmacokinetic/pharmacodynamic (PK/PD) and manageable safety profile in line with previous anti-PD1 development and with a high signal of efficacy in the first 20 patients representing 13 different tumor types. Positive Phase 1/2 analysis from first use of FR104/VEL-101 immunotherapy in kidney transplantation. In June 2024, OSE Immunotherapeutics and Nantes University Hospital presented positive data from the completed Phase 1/2 clinical trial FIRsT evaluating FR104/VEL-101 in patients undergoing renal transplant at the « American Transplant Congress » (ATC) in Philadelphia. The data showed the safety of the product used in combination and the first signs of efficacy with no episodes of acute rejection after one year follow-up in the 8 patients of the study who completed 1-year treatment. Two additional oral communications were presented during this congress: A communication presented by OSE partner Veloxis Pharmaceuticals, featured the results from its Phase 1 dose escalation clinical trial evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of single ascending doses of subcutaneous administration of FR104/VEL-101 in healthy participants.A communication presented by the group of Pr. Richard Pierson (Massachusetts General Hospital, Harvard university, Boston, USA), reported on the positive preclinical efficacy data of FR104/VEL-101 injection in monotherapy or in combination with anti-CD40L antibody to protect from acute and chronic heart allograft rejection. Advancement of clinical development of first-in-class SIRPα cancer immunology treatment BI 770371 In July 2024, Boehringer Ingelheim and OSE Immunotherapeutics announced that Boehringer Ingelheim will be progressing their first-in-class SIRPα immuno-oncology program into the next phase in clinical development. As part of the program, Boehringer will move forward with an improved next generation SIRPα inhibitor antibody, which will now be tested in a Phase 1b study in solid tumors.The initiation of a Phase 2 study in cardiovascular-renal-metabolic (CRM) diseases is planned for the end of 2024. PROGRESS ON EARLY-STAGE PROGRAMS In April 2024, novel data in the peer-reviewed Journal of Immunology on a first-in-class research program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The collaborative work with Dr Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology has shown, for the first time, that CLEC-1 acts as an immune checkpoint for the control of acute immune responses in the context of sterile inflammation.In June 2024, the Company presented preclinical data on novel mRNA (messenger RiboNucleic Acid) Therapeutic platform for the treatment of inflammatory and autoimmune disorders at the Federation of Clinical Immunology Societies (FOCIS) annual meeting held in San Francisco. The mRNA therapeutic platform has been designed for the local delivery of mRNA into inflammatory tissue using lipid nanoparticles. This platform has the potential to deliver innovative immunotherapeutic drugs and to address new biology that cannot be targeted with standard biologic treatments. This novel IL-35 mRNA therapeutics is generating potential opportunities for the treatment of inflammatory and autoimmune disorders, in particular in autoimmune hepatitis, a severe immune-mediated inflammatory disorder of the liver with strong unmet medical need. In June 2024, OSE Immunotherapeutics also entered into a commercial and revenue sharing agreement with leading global cancer center Memorial Sloan Kettering Cancer Center (MSK). This exclusive and worldwide agreement covers OSE Immunotherapeutics’ patent rights and jointly owned OSE/MSK patent rights in the field of Chimeric Antigen Receptor (CAR) cell therapy for the treatment of Interleukin-7 Receptor (IL-7R) expressing cancers, in particular hematological tumors such as Acute Lymphoblastic Leukemia. As part of this agreement, MSK will lead the research, development, and commercialization efforts, and subsequently share potential future revenues with OSE Immunotherapeutics. CORPORATE GOVERNANCE Marc Dechamps, Martine George, Markus Goebel and Cécile Nguyen-Cluzel were appointed new independent Directors of OSE Immunotherapeutics on June 19, 2024. Together, they bring a wealth of experience from leadership roles in the biopharmaceutical and health financial industry reenforcing the key strategic skills of the Board.The newly installed Board appointed Didier Hoch as its Chairman. He succeeds Dominique Costantini who did not run for a new mandate at the 2024 Shareholders’ meeting. H1 2024 RESULTSThe key figures of the 2024 consolidated half-year results are reported below: In k€June 30, 2024June 30, 2023Operating result63,321(13,504)Net result57,175(11,860)In k€June 30, 2024December 31, 2023Available cash and cash equivalents25,85618,672Financial assets (deposit > 3 months)49,8900Consolidated balance sheet140,92182,054 As of June 30, 2024, available cash (1) and financial assets (2) amounted to €80.7 million, giving a financial visibility until 2027. During the first half of 2024, the Company secured: $48 million upfront payment as part of global license and collaboration agreement with AbbVie for ABBV-230 (formerly OSE-230), a novel monoclonal antibody for the treatment of chronic inflammation.€13.5 upfront payment as part of a purchase agreement with Boehringer Ingelheim of a novel cis-targeting anti-PD-1/cytokine asset developed by OSE.€25.3 million one-time payment as part of an amendment of the existing collaboration and licensing agreement with Boehringer Ingelheim for the anti-SIRPα immuno-oncology compounds BI 765063 and BI 770371.€5.8 million in 2023 research tax credit.€8.4 million in public funding under the “i-Démo” call for projects as part of the plan “France 2030” to support the registration Phase 3 clinical trial of cancer vaccine Tedopi® in NSCLC. This financing will be spread over the life of the project. This available cash will enable the Company to finance its clinical development and R&D costs for earlier stage products. During the first half of 2024, the Company recorded a consolidated net result of €57.2 million. Current operating expenses were €19.3 million (versus €14.9 million for the same period in 2023) of which 77% are related to R&D. The Board of Directors of September 26, 2024, has approved the Company’s semester accounts as of June 30, 2024. The full “Half-year financial report” (Regulated information) is available on: https://www.ose-immuno.com/en/financial-documents/. The limited review procedures on the consolidated accounts have been performed. The report on this limited review is being issued. CONSOLIDATED PROFIT & LOSS In K€ H1 2024H1 2023Turnover 69,0461,358Other products 13,5270 OPERATING INCOME - RECURRING 82,5731,358Research & Development expenses (13,884)(9,693)Overhead expenses (4,286)(3,604)Expenses related to share-based payments (1,082)(1,562) OPERATING PROFIT/LOSS - RECURRING 63,321(13,501)Other operating income and expenses 0(4) OPERATING RESULT 63,321(13,504)Financial income 3912,658Financial expenses (2,998)(1,608) PROFIT/LOSS BEFORE TAX (2,606)(11,943) INCOME TAX 3,54084 CONSOLIDATED NET RESULT 57,175(11,860) Of which consolidated net result attributable to shareholders57,175(11,860)Net earnings attributable to shareholders Weighted average number of shares outstanding 21,759,03518,624,665 The basic and diluted result per common share (€/share) 2.63(0.64) Diluted result per share 2.27(0.64) In K€ H1 2024H1 2023 NET RESULT 57,175(11,860) Amounts to be recycled in the income statement: Unrealized gains on securities available for sale, net of tax Currency conversion difference 42(7) Amounts not to be recycled in the income statement: Actuarial gains and losses on post-employment benefits 0Other comprehensive income in the period (42)(7) GLOBAL PROFIT/LOSS 57,217(11,867) CONSOLIDATED BALANCE SHEET ASSETS in K€ June 30, 2024December 31, 2023NON-CURRENT ASSETS Acquired R&D costs 45,21146,401Tangible assets 386464Rights of use 3,2613,606Financial assets 6,084910Deferred tax assets 195195TOTAL NON-CURRENT ASSETS 55,13651,576 CURRENT ASSETS Trade receivables4,966982Other current assets 54,96310,824Cash and cash equivalents25,85618,672TOTAL CURRENT ASSETS 85,78530,478 TOTAL ASSETS 140,92182,054 EQUITY & LIABILITIES in K€ June 30, 2024December 31, 2023 SHAREHOLDERS’ EQUITY Stated capital 4,3664,330Share & Merger premium 76,82276,643Treasury stock (393)(408)Reserves and retained earnings(56,522)(34,587)Consolidated result 57,175(23,003)TOTAL SHAREHOLDERS’ EQUITY 81,44822,975NON-CURRENT DEBTS Non-current financial liabilities Lease non current liabilities37,15235,508Non-current lease liabilities 2,8123,032Non-current deferred tax liabilities 1,6581,311Non-current provisions 464429TOTAL NON-CURRENT DEBTS 42,08640,280 CURRENT DEBTS Current financial liabilities3,2366,403Current lease liabilities685858Trade payables8,3449,299Corporate income tax liabilities 020Social and tax payables 2,2191,867Other debts and accruals 2,901351TOTAL CURRENT DEBTS 17,38718,799 TOTAL LIABILITIES140,92182,054 About OSE Immunotherapeutics OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The Company’s current well-balanced first-in-class clinical pipeline includes: Tedopi® (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): most advanced therapeutic cancer vaccine in development; positive results from a randomized Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in third-line secondary resistance after checkpoint inhibitor failure. Ongoing randomized registration Phase 3 study (Artemia) in second-line NSCLC in HLA-A2+ patients with secondary resistance. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors. OSE-127 - Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); Positive Phase 2 (CoTikiS) study in Ulcerative Colitis; ongoing preclinical research in leukemia. OSE-279 (anti-PD1): first positive results in the ongoing Phase 1/2 in solid tumors. FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals, Inc.).Anti-SIRPα monoclonal antibody developed in partnership with Boehringer Ingelheim in advanced solid tumors and cardiovascular-renal-metabolic diseases (CRM); positive Phase 1 dose escalation results in monotherapy and in combination; Phase 2 in CRM diseases planned to be initiated end of 2024.ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies: Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution and optimizing the therapeutic potential of targeting Neutrophils and Macrophages in I&I. ABBV-230 (licensed to AbbVie) is the first candidate generated by the platform, additional discovery programs ongoing on new pro-resolutive GPCRs.Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO by targeting immune regulatory receptors expressed by Macrophages and Dendritic cells. BI 765063 and BI 770371 (licensed to Boehringer Ingelheim) are the most advanced candidates generated by the platform. Ongoing additional discovery programs, in particular with positive preclinical results obtained in monotherapy with new anti-CLEC-1 mAbs.BiCKI® Platform is a bifunctional fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy by “cis-potentiating” tumor-specific T cells. A first program has been acquired by Boehringer Ingelheim.mRNA Therapeutic platform allows local delivery into the inflammatory site of innovative immunotherapies encoded by RNA to locally controls and/or suppress immune responses and inflammation. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on X and LinkedIn Contacts Sylvie Détrysylvie.detry@ose-immuno.comNicolas PoirierChief Executive Officer nicolas.poirier@ose-immuno.comFrench Media: FP2COMFlorence Portejoiefportejoie@fp2com.fr+33 6 07 768 283U.S. Media ContactRooneyPartners LLCKate Barrettekbarrette@rooneypartners.com+1 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. 1 Cash & cash equivalent2 Non-current & current financial assets are deposit which maturity > 3 months (IAS 7); classified as non-current for deposits with maturities > 12 months3 Cis-targeting: Bispecific antibodies have the capability to target cells either in a cis- or in a trans-binding orientation. During trans-binding, the antibody recognizes two different antigens, each expressed on a different cell population, and can link two different cell populations with each other (e.g. T-cell engagers). Cis-binding bispecific antibody targets two antigens expressed on the very same cell enabling preferential activation of the desired immune cell types while minimizing the activation of others (Segués A. et al. International Review of Cell and Molecular Biology 2022). Attachment EN_240926_Half-year results

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 Philadelphia) Nantes, France – June 5, 2024, 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Nantes University Hospital present positive Phase 1/2 analysis from first use of anti-CD28 FR104/VEL-101 in kidney transplantation in oral presentation at the Annual American Transplant Congress (ATC) held in Philadelphia (June 1-5, 2024). A total of three oral presentations on FR104/VEL-101 were presented at this congress. A first oral communication, entitled “First use of FR104, an anti-CD28 molecule in human kidney transplantation”, presented by Pr. Gilles Blancho, Head of the ITUN* at the University Hospital in Nantes / Nantes University and Principal Investigator of the study, reported on the positive data from the completed Phase 1/2 clinical trial FIRsT evaluating FR104/VEL-101 in patients undergoing renal allotransplant. This study is sponsored and conducted by the University Hospital of Nantes as part of a collaboration agreement with OSE Immunotherapeutics. A second oral communication, entitled “Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Fixed-Dose, Subcutaneous (SQ) Administration of VEL-101, an Anti-CD28 Pegylated Monoclonal Antibody Fragment, in Healthy Participants”, presented by OSE Immunotherapeutics partner Veloxis Pharmaceuticals, featured the results from the Company’s Phase 1 dose escalation clinical trial evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of single ascending doses of subcutaneous administration of FR104/VEL-101 in healthy participants. A third oral communication, entitled “Combined blockade of the CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunity and prolongs survival in cynomolgus cardiac allografts”, presented by the group of Pr. Richard Pierson (Massachusetts General Hospital, Harvard university, Boston, USA), reported on the positive preclinical efficacy data of FR104/VEL-101 injection in monotherapy or in combination with anti-CD40L antibody to protect from acute and chronic heart allograft rejection. Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, said: “We thank the University Hospital of Nantes for this important step with the first clinical study evaluating FR104/VEL-101 in transplanted patients. Our partner Veloxis presented its positive subcutaneous Phase 1 clinical trial results in oral session, which will facilitate dose selection in preparation for a Phase 2 study in kidney transplant recipients. At last, we are excited about the promising preclinical results of our academic collaborator in the field of cardiac transplantation, further enhancing the future market potential.” Pr. Gilles Blancho commented: « We are very pleased to share the positive results of the FIRsT study at international congress on post-transplant immune response and one-year safety in patients treated with FR104/VEL-101, developed for years in our own research laboratory, CR2TI**/UMR Inserm 1064. The data presented show the safety of the product used in combination and the first signs of efficacy in kidney transplant recipients with no episodes of acute rejection after one year follow-up in all patients of the study. The exploration of FR104/VEL-101’s safety profile seems promising and encourages moving to a Phase 2 trial for patients undergoing renal transplant who require innovative solution.” The purpose of the FIRsT Phase 1/2 clinical trial is to investigate the safety, tolerability, and pharmacokinetics of FR104/VEL-101, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment, as well as its potential clinical efficacy on acute rejection prophylaxis and renal function in a de novo renal transplant population receiving an allograft from standard criteria donors (NCT number: NCT04837092). A one-year safety and efficacy of FR-104/VEL-101 treatment assessment was performed after transplantation, including renal function, incidence of rejection and suspected reported adverse events. Ten patient candidates eligible to a first kidney transplant at low risk of rejection, as planned in the protocol, have been included in the FIRsT study for eight analyzable patients (two patients were screened and enrolled but not transplanted for technical reasons). Tacrolimus (a calcineurin inhibitor) was withdrawn after 6 months post-transplantation. The eight patients completed 1-year treatment with FR104/VEL-101. No safety alert was detected for FR104/VEL-101. Adverse events were those conventionally observed in kidney transplantation. Pharmacological monitoring made it possible to optimize exposure to FR104/VEL-101 and to maintain high receptor occupancy during the one-year follow-up. With a follow-up of 1 year in all patients, not only no acute rejection under FR104/VEL-101 was observed, and notably no acute rejection episodes occurred after discontinuation of tacrolimus, but also no immunization against the donor occurred. One of the key challenges in organ transplantation remains calcineurin inhibitors alternatives with effective immunosuppressive treatments and minimal side effects, particularly on renal function in order to preserve patients’ quality of life, and long-term control of post-transplant immune reaction. * Urology and Nephrology Transplant Institute (ITUN) ** Center for Research in Transplantation and Translational Immunology (CR2TI) DETAILS OF THE PRESENTATIONSOSE IMMUNOTHERAPEUTICS“First Use of FR104, an Anti-CD28 Molecule in Human Kidney Transplantation, Interim Analysis” Rapid Fire Oral Abstract SessionAbstract 1050Tuesday, June 04 - 3:50PM – 4 :00PM G. J. Blancho, Institute of Transplantation - Urologie - Nephrologie (ITUN), Centre Hospitalier Universitaire, Nantes, FranceVELOXIS PHARMACEUTICALS“Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Fixed-Dose, Subcutaneous (SQ) Administration of VEL-101, an Anti-CD28 Pegylated Monoclonal Antibody Fragment, in Healthy Participants” Rapid Fire Oral Abstract SessionAbstract 1049Tuesday, June 04 - 3:40PM 3:50PM S. Tremblay {1}, A. Abaigar{2}, P. Allton{1}, D. Sardinha{1}, S. Patel{1}, U. Meier-Kriesche{1}, K. Shah{1}, J. Maynard{3}, B. Otulana{1}, {1}Veloxis Pharmaceuticals, Cary, NC, {2}CTI Clinical Trial & Consulting Services, Bilbao, Spain, {3}CTI Clinical Trial & Consulting Services, Cincinnati, OHCENTER FOR TRANSPLANTATION SCIENCES, MASSACHUSETTS GENERAL HOSPITAL, HARVARD UNIVERSITY, BOSTON“Combined blockade of the CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunity and prolongs survival in cynomolgus cardiac allografts” Rapid Fire Oral Abstract Session Abstract 860Tuesday, June 04 - 9:45AM 9:55PM Kohei Kinoshita1, A Maenaka1, Z Habibabady1, I Ileka1, M Ma1, V Diaz1, T Zhang3, N O’Neill3, I Rosales2, S Fogarty4, P Maguire4, B Daugherty4, S Lederman4, U Meier-Kriesche5, N Poirier6, A Azimzadeh1,3, R Pierson III1, 1Center for Transplantation Sciences, Massachusetts General Hospital, Boston, 2 Department of Pathology, Massachusetts General Hospital, Boston, , 3 University of Maryland School of Medicine, Baltimore, 4 Tonix Pharmaceuticals, 5 Veloxis Pharmaceuticals, 6 OSE Immunotherapeutics ABOUT FR104/VEL-101 FR104/VEL-101 is a pegylated monoclonal antibody fragment that binds to and blocks CD28-mediated effector-T cell co-stimulation, without blocking CTLA-4, an important protein receptor found on T cells that acts as a natural brake on the body’s immune responses. FR104/VEL-101 is, therefore, expected to have a dual-mechanism of action where in a direct manner, it blocks CD28-mediated T cell activation, and in an indirect way, it allows for CTLA-4 mediated immunosuppressive functions. ABOUT VELOXIS PHARMACEUTICALS Veloxis Pharmaceuticals, an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, N.C., USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases. For further information, please visit www.veloxis.com. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The Company’s current well-balanced first-in-class clinical pipeline includes: Tedopi® (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company’s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi® in combination are ongoing in solid tumors.OSE-279 (anti-PD1): first positive results in the ongoing Phase 1/2 in solid tumors. OSE-127 - lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics).FR-104/VEL-101 (anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1/2 in renal transplant (sponsor Nantes University Hospital); successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals, Inc.).Anti-SIRPα monoclonal antibody developed in partnership with Boehringer Ingelheim in advanced solid tumors and cardiovascular-renal-metabolic diseases (CRM); positive Phase 1 dose escalation results in monotherapy and in combination; Phase 2 in CRM diseases planned to be initiated end of 2024.OSE-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies: Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution and optimizing the therapeutic potential of targeting Neutrophils and Macrophages in I&I. OSE-230 (licensed to AbbVie) is the first candidate generated by the platform, additional discovery programs ongoing on new pro-resolutive GPCRs.Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO by targeting immune regulatory receptors expressed by Macrophages and Dendritic cells. BI 765063 and BI 770371 (licensed to Boehringer Ingelheim) are the most advanced candidates generated by the platform. Ongoing additional discovery programs, in particular with positive preclinical results obtained in monotherapy with new anti-CLEC-1 mAbs. BiCKI® Platform is a bifunctional fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com. Follow us on X and LinkedIn. Contacts Sylvie Détrysylvie.detry@ose-immuno.comNicolas PoirierChief Executive Officer nicolas.poirier@ose-immuno.comFrench Media: FP2COMFlorence Portejoiefportejoie@fp2com.fr+33 6 07 768 283U.S. Media ContactRooneyPartners LLCKate Barrettekbarrette@rooneypartners.com+1 212 223 0561 Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_240605_FR104 ATC

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera Heart donor-derived cfDNA (dd-cfDNA) test to detect rejection in adult and pediatric heart transplant recipients. These are the second and third peer-reviewed publications evaluating Natera’s technology for use in heart transplantation. “We are encouraged by the results of these two prospective studies,” said Sangeeta Bhorade, MD, chief medical officer of organ health at Natera. “The consistent, excellent performance of Prospera Heart across multiple independent studies should inspire confidence among transplant physicians to leverage Prospera as part of standard patient care.” The Prospera Heart test was launched in 2021 and received Medicare coverage following the 2022 publication of a multi-site clinical validation study, the DEDUCE study, in the Journal of Heart and Lung Transplantation. That study showed the Prospera Heart test had an overall area under the curve (AUC) of 0.86 for identifying acute rejection in over 800 samples from 200 adults with heart transplants. The DTRT-2 (DNA-Based Transplant Rejection Test) study, published recently in Pediatric Transplantation, was sponsored by the National Institutes of Health (NIH). A total of 487 samples from 160 heart transplant recipients were evaluated, of which 78 were pediatric and 82 were adult patients. The Prospera Heart test demonstrated outstanding performance in detecting rejection, as determined by histopathology from endomyocardial biopsies (EMBs), with an AUC of 0.82 in adult patients and 0.83 in pediatric patients. The study reported a negative predictive value (NPV) of 92% for adult patients and 99% for pediatric patients, supporting the intended use of Prospera Heart as a rule-out test to help obviate surveillance biopsy procedures. “DTRT-2 is a landmark study that further demonstrates that the Prospera Heart test is a highly reliable, non-invasive tool for detecting heart transplant rejection in adult patients, and now solidifies that outstanding performance for pediatric patients as well,” said Shriprasad R. Deshpande, MBBS, MS, director of the Advanced Cardiac on Therapies and Heart Transplant Program, Children’s National Hospital, and lead author of the study. “Based on these findings, I believe the Prospera Heart test has the potential to greatly reduce the number of invasive surveillance biopsies in children and enhance their quality of life.” The Trifecta-Heart study had its initial publication last week in Transplantation and has an upcoming oral presentation at the 2024 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. This initial readout included 137 plasma samples analyzed using the Prospera Heart test, correlated with matched EMBs analyzed using the Molecular Microscope® Diagnostic System (MMDx), a more objective reference standard for rejection compared to histopathology. Based on data collected in the first 18 months, the Prospera Heart test was highly accurate in distinguishing acute rejection from non-rejection, with an AUC of 0.90 and a NPV of 96%. These results affirm the strong performance of Prospera Heart shown in the DEDUCE study. Roughly 4,100 heart transplants are performed each year in the U.S., including about 490 pediatric recipients in 2022.1 Biopsies, which are the current standard of care for heart transplant surveillance, have a complication rate ranging between 1-5%.2-6 Further, due to modern immunosuppression regimens, acute rejection rates, as detected by surveillance biopsies, are now lower than the rate of biopsy complications.7 This highlights the imbalance in risk versus reward and argues in favor of a non-invasive alternative to monitor for rejection. These latest data come just before the 2024 ISHLT Annual Meeting, where Natera will deliver one oral presentation and six poster presentations related to its Prospera Heart and Prospera Lung tests. About the Prospera test The ProsperaTM test leverages Natera’s core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient’s blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation. About Natera NateraTM is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 180 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit . Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, or our expectations of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and . References Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2022 Annual Data Report: Heart. U.S. Department of Health and Human Services, Health Resources and Services Administration. 2024. Accessed April 4, 2024. Bermpeis K, Esposito G, Gallinoro E, et al. Safety of right and left ventricular endomyocardial biopsy in heart transplantation and cardio-myopathy patients. JACC Heart Fail. 2022;10:963–973. Strecker T, Rösch J, Weyand M, et al. Endomyocardial biopsy for monitoring heart transplant patients: 11-years-experience at a German heart center. Int J Clin Exp Pathol. 2013;6:55–65. Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardio-myopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol. 1992;19:43–47. Hamour IM, Burke MM, Bell AD, et al. Limited utility of endomyocardial biopsy in the first year after heart transplantation. Transplantation. 2008;85:969–974. Hull JV, Padkins MR, Hajj SE, et al. Risks of right heart catheterization and right ventricular biopsy: a 12-year, single-center experience. Mayo Clin Proc. 2023;98:419–431. Cusi V, Vaida F, Wettersten N, et al. Incidence of Acute Rejection Compared With Endomyocardial Biopsy Complications for Heart Transplant Patients in the Contemporary Era. Transplantation. 2023. Epub ahead of print. PMID: 38098137.